SGMT Company Profile and Key Details

SGMT has shown mixed momentum, gaining 0.64% over the past week and -14.67% over the past quarter, though year-to-date performance is up 6.08%. Short-term trend indicators are bullishly aligned (SMA20 5.07%, SMA50 0.21%, SMA200 -15.13%). The stock’s 14-day RSI is 52.88 (neutral), while the ATR of 0.42 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.55% below its high and over 239.31% above its low. Average 10-day trading volume of 1.46 million shares is below the 3-month average of 1.65 million, indicating normal recent market interest.

Sagimet Biosciences Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading above this model’s fair value.

Sagimet Biosciences Inc. has 31.00 million shares outstanding. The public float is 22.63 million shares, elevated short interest at 11.31% of float. This equals 3.21 million shares. The short ratio is 3.87 days. Institutional investors hold 22.72% of the float. Insiders own 3.5%. NEW ENTERPRISE ASSOCIATES 13 LP holds 3.82 million shares, Happel David has 677.62 thousand shares and Rozek Elizabeth has 190.96 thousand shares. Over the past six months, insider transactions show net selling. They sold 19.68 thousand shares across 4 transactions.

Sagimet Biosciences Inc. generated EPS of -$1.79 over the past year. Five-year average earnings growth is -16.85%. Wall Street analysts project EPS growth of -13.95% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $49.00 to $8.00. The high target offers 590.14% upside. The low target suggests 12.68% downside. The mean target is $27.38. This offers 285.63% upside. Sagimet Biosciences Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -15.38%. The prior quarter beat by -32.56%. Over the last six quarters, Apple has recorded several small beats. These include -23.08% in March 12, 2025.

Sagimet Biosciences Inc. (NASDAQ:SGMT) closed at $7.10 USD, gaining $0.42 (6.29%) from the previous close of $6.68. The stock is currently mid-range between its 52-week high and low $4.50 and $11.41. With a market capitalization of about $231.33 million, Sagimet Biosciences Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.44). Key stats such as the average daily volume over the past year has been around 1.60 million shares, volume is running light vs its 52-week average. Headquartered in San Mateo, CA, Sagimet Biosciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David A. Happel, the company employs approximately 14 people and listed since July 17, 2023. Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition.

Sagimet Biosciences Inc. trades at a P/E ratio of -5.19, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.22 suggesting the stock is closer to book value. The P/FCF stands at -5.74, also above market averages.

Our AI price prediction model suggests that Sagimet Biosciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.79%, with price expected at $6.76 by July 06, 2026, within a range of $6.46 to $7.07 3-Month Outlook: Projected rise of 71.69%, reaching $12.19 by September 16, 2026, with a range of $11.90 to $12.52. 1-Year Outlook: Projected gain of 117.18%, with price at $15.42 by June 22, 2027, within a range of $0.71 to $26.76.

Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are flat 6.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Sagimet Biosciences Inc. trading at a premium to the broader market with a P/E of -5.19. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $28.54, suggesting 301.97% upside. Our AI forecast model points to short-term weakness (-4.79% over two weeks), a medium-term rise (71.69% over three months), and a longer-term gain (117.18% over one year), with expected trading ranges indicating moderate volatility.